Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fatty Acid Type Clear all
Completed Phase 1 Interventional

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

NCT02278965
View directory record Official record
Conditions
Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
Interventions
Metformin, Omega-3 fatty acids
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Loss and Glucose Metabolism in People With Family History of Type 2 Diabetes.

NCT00721019
View directory record Official record
Conditions
Sleep, Sleep Deprivation, Insulin Resistance, Type 2 Diabetes
Interventions
5-hour bedtime, 8.5-hour bedtimes
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

NCT00323414
View directory record Official record
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated No phase listed Observational

A Study to Identify and Characterize LAL-D Patients in High-risk Populations

NCT02345421
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions
Metformin Eicosapentaenoate, Metformin HCl and Vascepa
Drug
Lead sponsor
Thetis Pharmaceuticals LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 1 Interventional

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

NCT05144347
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
XL114
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Tucson, Arizona • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids

NCT00479791
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Test meals rich in different fatty acids
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2007 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

NCT03406897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
Interventions
Cholecalciferol, Omega 3 fatty acid
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
6 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 14, 2026, 10:47 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Milk Fat Intake and Metabolic Health Markers

NCT02659748
View directory record Official record
Conditions
Insulin Sensitivity, Type 2 Diabetes
Interventions
Milk Fat, Control Fat
Dietary Supplement
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 14, 2026, 10:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fatty Acid Regulation of Platelet Function in Diabetes

NCT02373332
View directory record Official record
Conditions
Thrombosis, Type 2 Diabetes Mellitus
Interventions
omega-3 and -6 fatty acids and their 12-LOX oxylipins
Other
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 14, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739
View directory record Official record
Conditions
Prediabetes, Obesity
Interventions
Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 14, 2026, 10:47 AM EDT
Not listed No phase listed Observational

Risk Stratification of COVID-19 Using Urine Biomarkers

NCT04681040
View directory record Official record
Conditions
Covid19, Urine, Biomarker, Acute Respiratory Failure With Hypoxia
Interventions
Not listed
Lead sponsor
National Center for Global Health and Medicine, Japan
Government
Eligibility
20 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

NCT02476994
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Up to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Park Ridge, Illinois • Indianapolis, Indiana • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Mitochondrial Dysfunction in Type 2 Diabetes Mellitus and Capacity for Fat Oxidation During Exercise

NCT00382473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Overweight
Interventions
Aerobic exercise program - 8 weeks
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
28 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 14, 2026, 10:47 AM EDT
Recruiting No phase listed Observational

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Interventions
Omegaven® (fish oil triglycerides) Injectable Emulsion
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
1 Day to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

NCT01648296
View directory record Official record
Conditions
Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
Interventions
[18F]FluorbetaOx
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus

NCT02629497
View directory record Official record
Conditions
Thrombosis, Type 2 Diabetes Mellitus
Interventions
Primrose oil, Fish Oil
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 14, 2026, 10:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

NCT04006847
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
Eicosapentaenoic Acid, Tyrosine kinase inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus

NCT00607945
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant, conjugated linoleic acid (CLA)
Drug · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
30 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Free Fatty Acids and Vascular Function in Subjects With Diabetes

NCT00153179
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
acipimox, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes

NCT00592072
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Medium chain fatty acid (Octanoic and Decanoic acid), Splenda (Placebo Control)
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 14, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

NCT04555044
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
0 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • New Haven, Connecticut • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 14, 2026, 10:47 AM EDT